Wire open Last filed Retatrutide Ozempic trial shows bigger A1C drop and double the weight loss RSS
Peptide Zone

Peptide medicine news,
filed as it happens.

Morning wire

Peptide medicine news, filed as it happens

Peptide Zone is a news wire for peptide medicines such as GLP-1 drugs, amylin analogues and peptide vaccines. Each story covers one regulator decision, trial readout, industry deal or safety review, names its primary source and says what comes next. Nothing here is medical advice. About the newsroom

FlashTRLNews

Retatrutide Ozempic trial shows bigger A1C drop and double the weight loss

Lilly says retatrutide cut A1C by 2.2 points and weight by up to 20.9% at 80 weeks in type 2 diabetes, against 1.8 points and 9.4% on Ozempic. More people stopped retatrutide for side effects, and the data are not yet peer reviewed.

INDIANAPOLIS

20.9% vs 9.4%Average weight loss at 80 weeks on the higher retatrutide dose versus Ozempic, per Lilly
  1. What's newLilly said retatrutide beat Ozempic at its highest approved diabetes dose in the Phase 3 TRANSCEND-T2D-2 trial, cutting A1C by 2.2 points against 1.8 and weight by up to 20.9% against 9.4% at 80 weeks.
  2. Why it mattersIt is the first Phase 3 test of retatrutide against another incretin drug, and it shows both a larger effect and more side effect dropouts than the comparator.
  3. What's nextFull data are due at a medical meeting and in a journal. An extension continues for 24 weeks, and the TRIUMPH-5 trial against tirzepatide is ongoing.

Latest on the wire

Full wire

The 60-second briefing

Five things filed most recently

  1. TRL · 28 Oct 2026Two Phase 3 trials published in NEJM found retatrutide cut breathing pauses in 691 adults with moderate to severe obstructive sleep apnea and overweight or obesity over 80 weeks, with and without type 2 diabetes.
  2. SAF · 28 Oct 2026A News-Medical review published 26 October summarises research on GLP 1 drugs and eating disorders, finding early but inconsistent signals in binge eating disorder and no evidence the drugs cause anorexia nervosa.
  3. IND · 27 Oct 2026The 2026 KFF Employer Health Benefits Survey finds GLP 1 coverage for weight loss flat at 18% of firms with 200 or more workers, with 40% of covering firms now requiring a lifestyle program or counselling.
  4. REG · 27 Oct 2026WADA left the status of GLP 1 receptor agonists unchanged in its 2027 Prohibited List, so semaglutide and tirzepatide stay permitted for athletes and remain on the Monitoring Program.
  5. SAF · 27 Oct 2026University of Queensland researchers say people who inject online peptides need needle program access and basic safety advice, and they set out five safety basics.

By the numbers

The one figure each story turns on.

28.7%average weight loss on the highest dose after 68 weeks TRL · 11 DEC · Retatrutide posts the largest average weight loss yet in a phase 3 trial 62.9%of treated patients saw liver inflammation resolve without fibrosis worsening, vs 34.3% on placebo REG · 15 AUG · Wegovy gets accelerated approval for fatty-liver disease with scarring 20.2%average weight loss on tirzepatide vs 13.7% on semaglutide after 72 weeks TRL · 11 MAY · Head to head, tirzepatide beats semaglutide on weight loss 1stprescription drug approved to treat obstructive sleep apnea in adults with obesity REG · 20 DEC · FDA clears tirzepatide as the first medicine for obstructive sleep apnea 6 of 7Peptides the FDA compounding advisory committee backed for the 503A Bulks List in July 2026 SAF · 26 OCT · JAMA Viewpoint warns peptide compounding vote threatens the FDA approval system 4 divisionsMinistry divisions that co-signed the October 14 notice recirculating the GLP 1 appropriate use rules SAF · 25 OCT · Japan reissues GLP 1 appropriate use notice with a ketosis warning for slimming use

Threads we are following

Storylines that span months. Each dot is a story, placed by date.

Thread · 4 stories

Copies, risks and rules

What can people legally get, and how do regulators react when demand outruns supply?

Dec 2024Oct 2026

  • 06 JUNEU safety committee adds a rare eye condition to semaglutide warnings
  • 21 FEBSemaglutide shortage declared over, starting the clock on compounded copies

Thread · 6 stories

The incretin race

Who ends up with the most weight loss, the fewest side effects and the easiest dosing?

Dec 2024Oct 2026

  • 07 AUGThe weight-loss pill that is not a peptide posts its first obesity readout
  • 12 MARRoche buys into petrelintide in a bet that amylin is the next act

Thread · 4 stories

Beyond the scale

Which organ benefits hold up in outcome trials, and which do not?

Dec 2024Oct 2026

  • 24 NOVSemaglutide fails to slow Alzheimer's in two large trials
  • 28 JANSemaglutide wins a kidney label after the FLOW outcome trial

Desk fronts

REGRegulators8
TRLTrials18
INDIndustry5
SAFSafety12
EXPExplainers2

Where this news came from

Primary source type of every story on the wire. How we label sources

  • Regulator11
  • Journal9
  • Company release12
  • Conference5
  • Our newsroom8